CONFERENCE ON THE FUTURE OF A HEALTHY EUROPE
“Taking part in the decision-making process on health priorities”
20 – 21 April 2022
14:30 – 16:00 CEST
Given the current situation of uncertainty, the conference will be organized in a digital format.
To virtually attend the conference, please register here (registration is mandatory)
The new frontier of personalized medicine (a medical model that proposes the personalization of health, with medical decisions, practices, and products tailored to the patient) is represented by Advanced Therapy Medicinal Products (ATMP), which offer opportunities for innovative treatment and are classified into four groups:
This project has received funding from the European Union’s Horizon 2020 research and innovation programme.
NIGHTINGALE will develop and validate an innovative set of integrated tools for significant Medical Emergencies response: a multi-technological toolkit that links the different actors involved in managing the emergency and will serve emergency physicians and non-medical civil protection agencies (firefighters, police, but also volunteers and citizens). The goal is to improve pre-hospital life support and triage substantially. In addition, the tools developed will allow a shared response between emergency medical services, non-medical civil protection personnel, volunteers, and citizens by increasing their "field of vision," information sharing, and communication between teams and those affected.
Protecting the value of vaccination during -and after-the COVID-19 pandemic across Europe: impact, experiences and perspectives from citizens’ and patients’ advocacy groups & relevant stakeholders
Active Citizenship Network (ACN), after the commitment on VaccinAction2021, it's launching its #VaccinAction2022, focused on supporting the need for strengthening adult vaccination in Europe and – starting from the citizens’ and healthcare stakeholders’ perspective - understanding the impact of COVID-19 pandemic and vaccination campaigns on the national immunization plans, protecting the value of the adult immunization and its gains.
Our work on improving vaccination rates follow the Commission’s health priorities stated in the EU4Health 2021-2027 (as well as the fight against cancer and reducing the number of antimicrobial-resistant infections).
Patients need to play a much bigger role in the fight against antimicrobial resistance (AMR), as they are directly involved in over-prescribing, overuse and self-medication, the scale and effect of which is still unknown. Despite there are many organizations interested in the issue of AMR, and the diversity of expertise and experience is vast, to date, there has been no consolidated effort globally to amalgamate these and provide a coherent guidance and support for patients’ engagement in tackling this global public health threat.
This project has received funding from the European Union’s Horizon 2020
"PROPHET - a PeRsOnalized Prevention roadmap for the future HEalThcare" will develop a Strategic Research and Innovation Agenda (SRIA) for Personalized Prevention to support the implementation of innovative, sustainable, and effective personalized programs to prevent common chronic diseases. Cittadinanzattiva ACN is particularly involved in raising awareness among citizens and patients on the potential of Personalized Prevention, specifically on the quality of life and health outcomes improvement, and the possibility of engaging them to define personalized preventive services accepted and used by the public.
In 1948 the World Health Organization defined health as "a state of complete physical, mental and social well-being and not merely the absence of disease or infirmity”.
Today, after more than 70 years, the WHO definition is more relevant than ever if we think of the holistic approach to "global health” at the time of the health emergency that we have been experiencing for about two years.
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU).
FACILITATE is a 4-year project launched by the Innovative Medicines Initiative (IMI). Its primary goal is to enable clinical trial participants to access and make use of their gathered during studies health data, to facilitate better shared medical decision-making among the health professionals involved in their care while simultaneously developing a method that allows data to be re-used in future research. FACILITATE will ensure that the whole process, from data collection to its destruction or anonymization, including its sharing and re-use, is legally and ethically compliant and aligned with the study participants' but also hospitals', academia, and industries' voices.
In FACILITATE, Cittadinanzattiva-ACN co-leads the WP6, the work package dedicated to communication and dissemination, particularly for coordinating the stakeholders' involvement.
This project has received funding from the European Union’s Horizon
BIORECER aims to ensure the environmental performance and traceability of the biological feedstock used by bio-based industries by deploying guidelines to strengthen the current certification procedures. Through this approach, bioproducts' added value, use, as well as social acceptance will be increased. In this project, Cittadinanzattiva ACN is mainly involved in coordinating and supporting the stakeholders' involvement process.
In line with its long-term commitment on therapeutic adherence, Active Citizenship Network (ACN) launched in the second half of 2021 a EU project with the aim to better contribute – starting from citizens’ and patients’ perspective – on understanding the impact of the COVID-19 pandemic on the therapeutic plans for chronic patients. The ultimate goal is to enhance the actions and reactions implemented by PAGs and relevant stakeholders in front of the community of experts and institutions.